OBI Pharma Posters at 2020 ASCO Virtual Annual Meeting for Adagloxad Simolenin, OBI-999 and OBI-3424

Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence Abstract: TPS599 / Poster: 91 Title: Phase III, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of adagloxad simolenin (OBI-822) and OBI-821 treatment in patients with early-stage triple-negative breast cancer (TNBC) at high risk for recurrence. Presenter: Hope S. Rugo, MD, FASCO University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA Session Title: Breast Cancer—Local/Regional/Adjuvant Session Date and Time: Friday, May 29, 2020. 8:00 a.m. — 11:00 a.m. Eastern Time https://meetinglibrary.asco.org/record/191690/abstract A phase I/II, open‑label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI‑999 in patients with advanced solid tumors. Abstract: TPS3657 / Poster: 387 Title: A phase I/II, open‑label, dose-escalation, and cohort-expansion study evaluating the safety, pharmacokinetics, and therapeutic activity of OBI‑999 in patients with advanced solid tumors. Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Presenter: Apostolia Maria Tsimberidou, MD, Ph.D, The University of Texas MD Anderson Cancer Center, Houston, TX Session Date and Time: Friday, May 29, 2020. 8:00 a.m. — 11:00 a.m. Eastern Time https://meetinglibrary.asco.org/record/191854/abstracth /wp-content/uploads/2020/12/ASCO20_Tsimberidou-R-OBI-999.mp3 A first-in-man phase I/II study of OBI-3424, an AKR1C3-selective bis-alkylating agent prodrug, in subjects with advanced cancer, including hepatocellular carcinoma (HCC) and castrate-resistant prostate cancer (CRPC). Abstract: TPS3658 / Poster: 388 Title: A first-in-man phase I/II study of OBI-3424, an AKR1C3-selective bis-alkylating agent prodrug, in subjects with advanced cancer, including hepatocellular carcinoma (HCC) and castrate-resistant prostate cancer (CRPC). Session Title: Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology Presenter: Apostolia Maria Tsimberidou, MD, Ph.D, The University of Texas MD Anderson Cancer Center, Houston, TX Session Date and Time: Friday, May 29, 2020. 8:00 a.m. — 11:00 a.m. Eastern Time https://meetinglibrary.asco.org/record/191750/abstract https://www.obipharma.com/wp-content/uploads/ASCO20_Tsimberidou-R-OBI3424.mp3

The release as fetched from its publisher. obipharma.com ↗